4CPS-090 Emtricitabine/elvitegravir/cobicistat/tenofovir: effects on lipid metabolism and renal function

BACKGROUND: Emtricitabine/elvitegravir/cobicistat/tenofovir (FTC/EVG/COBI/TAF) changes levels of cholesterol and triglyceride. PURPOSE: To assess the effect on lipid metabolism and renal function in patients with human immunodeficiency virus (HIV) treated with the antiretoviral FTC/EVG/COBI/TAF. MAT...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Hosp Pharm
Glavni autori: Navarro, M, Betancor, T, Calzado, G, Ramos, E, Gómez, E, Vera, M, Ferrer, A, Diaz, P, Suárez, M, Miguelez, M, Merino, J
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Section 4: Clinical pharmacy services
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535317/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.181
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items